L Revesz

Summary

Affiliation: Novartis Institutes for BioMedical Research

Publications

  1. ncbi Solid phase synthesis of a biased mini tetrapeptoid-library for the discovery of monodentate ITAM mimics as ZAP-70 inhibitors
    L Revesz
    Preclinical Research Novartis, Basel, Switzerland
    Bioorg Med Chem Lett 8:405-8. 1998
  2. ncbi Isolation and synthesis of a novel immunosuppressive 17alpha-substituted dammarane from the flour of the Palmyrah palm (Borassus flabellifer)
    L Revesz
    Novartis Pharma AG, Arthritis and Bone Research, Switzerland
    Bioorg Med Chem Lett 9:1521-6. 1999
  3. ncbi SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors
    L Revesz
    Arthritis and Bone Research, Novartis Pharma AG, Switzerland
    Bioorg Med Chem Lett 10:1261-4. 2000
  4. ncbi SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors
    Laszlo Revesz
    Arthritis and Bone Research, Novartis Pharma AG, CH 4002, Basel, Switzerland
    Bioorg Med Chem Lett 12:2109-12. 2002
  5. ncbi Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 14:3595-9. 2004
  6. ncbi SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 14:3601-5. 2004
  7. ncbi In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 20:4719-23. 2010
  8. ncbi In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 20:4715-8. 2010

Detail Information

Publications8

  1. ncbi Solid phase synthesis of a biased mini tetrapeptoid-library for the discovery of monodentate ITAM mimics as ZAP-70 inhibitors
    L Revesz
    Preclinical Research Novartis, Basel, Switzerland
    Bioorg Med Chem Lett 8:405-8. 1998
    ..Screening for ZAP-70 antagonism identified 8 as a novel selective monodentate ZAP-70 antagonist and lead in the search for new immunosuppressive drugs...
  2. ncbi Isolation and synthesis of a novel immunosuppressive 17alpha-substituted dammarane from the flour of the Palmyrah palm (Borassus flabellifer)
    L Revesz
    Novartis Pharma AG, Arthritis and Bone Research, Switzerland
    Bioorg Med Chem Lett 9:1521-6. 1999
    ..1 was shown to be an extremely potent immunosuppressant in vitro (MLR; IC50 = 10 ng/ml) and in vivo (DTH; ED50 = 0.01 mg/kg p.o.). A glucocorticoid like activity is excluded...
  3. ncbi SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors
    L Revesz
    Arthritis and Bone Research, Novartis Pharma AG, Switzerland
    Bioorg Med Chem Lett 10:1261-4. 2000
    ..In contrast to pyridinylimidazoles such as SB 203580, 11 did not inhibit human cytochrome P450 isoenzymes...
  4. ncbi SAR of 2,6-diamino-3,5-difluoropyridinyl substituted heterocycles as novel p38MAP kinase inhibitors
    Laszlo Revesz
    Arthritis and Bone Research, Novartis Pharma AG, CH 4002, Basel, Switzerland
    Bioorg Med Chem Lett 12:2109-12. 2002
    ..i.d.) and collagen induced arthritis (ED(50): 5 mg/kg po b.i.d.) with disease modifying properties based on histological analysis of the joints...
  5. ncbi Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 14:3595-9. 2004
    ..0 and 9.5 mg/kg p.o...
  6. ncbi SAR of benzoylpyridines and benzophenones as p38alpha MAP kinase inhibitors with oral activity
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, Arthritis and Bone Metabolism, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 14:3601-5. 2004
    ..5 and 8.6 mg/kg p.o. in CIA...
  7. ncbi In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 20:4719-23. 2010
    ..05-0.23 microM), less potent in cells (IC(50)<1.1 microM), but show good oral absorption. Compound 13E (100mg/kg po; bid) showed oral activity in rAIA and mCIA, with significant reduction of swelling and histological score...
  8. ncbi In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I
    Laszlo Revesz
    Novartis Institutes for BioMedical Research, CH 4002 Basel, Switzerland
    Bioorg Med Chem Lett 20:4715-8. 2010
    ....